Indian journal of ophthalmology · 2026
A retrospective study reporting the incidence, risk factors, and intraocular pressure rise in patients receiving intravitreal steroids for retinal inflammatory diseases in a tertiary eye care hospital of South India.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Senthilkumari Srinivasan, Sharmila Rajendrababu, Ishwarya Mani, Naresh Kannan B
Аннотация
PURPOSE: To investigate the incidence and risk factors for steroid-induced ocular hypertension (SI-OHT) in patients receiving intravitreal steroids for retinal inflammatory diseases.
METHODS: This retrospective observational study included patients who received either intravitreal triamcinolone acetonide (IVTA/TA group) or dexamethasone intravitreal implant (DEX group) for the management of retinal vascular diseases in the period of 2018-23. SI-OHT in those patients were followed up for 2 years. Steroid responders and nonresponders were characterized based on intraocular pressure (IOP) change from the baseline. The incidence, risk factors, and magnitude of IOP rise and its association with ocular and systemic illness were investigated.
RESULTS: Out of 1178 reviewed, 761 patients were excluded due to irregular follow-up. A total of 382 patients (382 eyes) who received either IVTA/DEX intravitreal implant during the study period were reviewed. The incidence of SI-OHT was found to be 46.3% (IVTA group) and 20.8% (DEX group) at 6 months, respectively. Among patients who received 2 mg IVTA dosage, 16.9% were steroid responders and 11.9% for the 4 mg group.
CONCLUSION: We found that the incidence of SI-OHT was higher in IVTA group as compared to DEX group. No dose-dependent incidence was observed in the case of IVTA group. Age, gender, number of injections, and myopia were not associated with the risk of SI-OHT. Renal disease showed a significant association with the risk of SI-OHT in the DEX group, and patients with TB, stroke, and other drug allergies experienced a fivefold greater increase in IOP values in those groups.
METHODS: This retrospective observational study included patients who received either intravitreal triamcinolone acetonide (IVTA/TA group) or dexamethasone intravitreal implant (DEX group) for the management of retinal vascular diseases in the period of 2018-23. SI-OHT in those patients were followed up for 2 years. Steroid responders and nonresponders were characterized based on intraocular pressure (IOP) change from the baseline. The incidence, risk factors, and magnitude of IOP rise and its association with ocular and systemic illness were investigated.
RESULTS: Out of 1178 reviewed, 761 patients were excluded due to irregular follow-up. A total of 382 patients (382 eyes) who received either IVTA/DEX intravitreal implant during the study period were reviewed. The incidence of SI-OHT was found to be 46.3% (IVTA group) and 20.8% (DEX group) at 6 months, respectively. Among patients who received 2 mg IVTA dosage, 16.9% were steroid responders and 11.9% for the 4 mg group.
CONCLUSION: We found that the incidence of SI-OHT was higher in IVTA group as compared to DEX group. No dose-dependent incidence was observed in the case of IVTA group. Age, gender, number of injections, and myopia were not associated with the risk of SI-OHT. Renal disease showed a significant association with the risk of SI-OHT in the DEX group, and patients with TB, stroke, and other drug allergies experienced a fivefold greater increase in IOP values in those groups.